Get better Answers
With Innovative, Adaptive Clinical Trials.
Berry Consultants ("Berry") is a scientific consulting company specializing in innovative adaptive clinical trial design, analysis, implementation, and software solutions for the pharmaceutical and medical device industry.
To seek efficient answers for new medical advancements, you need more. That’s why Berry offers innovative statisticians and software for the freedom to design and implement adaptive clinical trials. Get the answers you need from analysis to approval and beyond.
Innovative Trials, Better Outcomes.
Berry has extensive experience in the design, implementation, and software solutions of adaptive clinical trials across many medical disciplines. Adaptive trials can result in better insights, greater efficiency, better treatment for subject in a trial, and better information for regulators and the medical community. Here’s the Adaptive Trial Process.
Adaptive Clinical Trial Design
Allow the pre-specification of flexible components to the major aspects of a trial, like the treatment arms, the allocation to the different treatment arms, the patient population, and the sample size.
Trial Implementation
Our services include interim and final analyses for primary and key secondary efficacy endpoints, providing expert guidance on best practices for adaptive design implementation, and interacting with Data Safety Monitoring Boards (DSMB) for adaptive and platform trials.
Clinical Trial Software
Software solutions that help Biostatisticians rapidly design, compare, and simulate both fixed and adaptive trial designs through powerful, versatile and fast simulation tools.
Platform Trials
Innovative clinical trials that evaluate multiple treatments simultaneously and intended to continue beyond the evaluation of any one treatment, while maximizing statistical and clinical efficiency.
Latest News and Events
Episode 10, “Revisiting Seamless 2/3 Trial for GLP-1 Agonist"
In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better known as Trulicity.
Episode 9, “I-SPY 2 to GMB AGILE and Beyond"
In this episode of "In the Interim...," we sit down with Dr. Meredith Buxton to explore the evolution of platform trials from I-SPY 2 to GBM AGILE and Beyond.
Today’s episode, “External Data in Clinical Trials"
In this episode of "In the Interim...," Scott Berry and Kert Viele navigate the nuanced debate surrounding the integration of external data in clinical trials.
Episode 7, “Remembering Jimmie Savage"
In today's podcast episode, discover more about Jimmie Savage—the man who shaped Bayesian statistics and left an indelible mark on the field.
Latest Publications
We’re continually refining and reshaping the clinical trials for the betterment of our clients and their patients.
